Aldariz A E, Romero H, Baroni M, Baglivo H, Esper R J
Pacing Clin Electrophysiol. 1986 Nov;9(6):836-41. doi: 10.1111/j.1540-8159.1986.tb06633.x.
A 65-year-old man with arterial hypertension received oral treatment with Ketanserin, a new drug, during a period of five months. He developed marked QT interval prolongation and have several Stokes-Adams attacks. A Holter recording obtained during one of these episodes showed torsade de pointes ventricular tachycardia. The arrhythmias occurred during maximum QT interval prolongation. The correlation between Ketanserin and QT interval prolongation was evaluated by using several Holter studies during administration and withdrawal of the drug. The effect of Ketanserin on the QTc interval was analyzed retrospectively in six patients who had been taking the drug orally. Following a period of four to eight months, the QTc interval was prolonged by the drug (5 to 31%, mean 17%) in five patients. We conclude that torsade de pointes is a potential hazard of long-term treatment with Ketanserin.
一名65岁的动脉高血压男性在五个月的时间里接受了新型药物酮色林的口服治疗。他出现了明显的QT间期延长，并发生了几次斯托克斯-亚当斯发作。在其中一次发作期间进行的动态心电图记录显示为尖端扭转型室性心动过速。心律失常发生在QT间期延长的最大值时。通过在给药和停药期间进行多次动态心电图研究，评估了酮色林与QT间期延长之间的相关性。对六名口服该药物的患者的QTc间期受酮色林影响的情况进行了回顾性分析。在四至八个月的时间后，五名患者的QTc间期被该药物延长了（5%至31%，平均17%）。我们得出结论，尖端扭转型室性心动过速是长期使用酮色林治疗的潜在风险。
